Case study: K Pro Reports

Owkin’s reports identify better patient subgroup biomarkers

Commission a report analysing patient heterogeneity and expression patterns of relevant genes in 10 cancer indications. 

Owkin’s reports - through K Pro - offer better biological understanding than competitors’ as they retain spatial biological information, unlike reports only relying on bulk RNA sequencing datasets.

Go beyond basic tumour-level target expression. Use our deeply differentiated insights to support data-driven hypotheses and optimize your asset positioning. 

‍

‍

Owkin’s proprietary MOSAIC multimodal data gives you what simple bulk RNA can’t

• Identify spatial specific biomarkers for patient selection - find biomarkers for the best responder populations.
• See tumour heterogeneity at single cell level and explore the spatial organization of the tumour microenvironment - ensure target cells express your gene of interest.
• Stratify your patient population with highly detailed, expert-curated, clinical data (including line of treatment, overall clinical outcome, and longitudinal data) - refine your clinical trial by clinico-pathological features.

‍

Our agentic AI enhances the data further 

• Owkin’s Pathology Explorer augments histology slides (H&E) for individual cell-type quantification and analysis.
• State-of-the-art deconvolution algorithms use information extracted from single-cell patient data to increase the resolution of spatial transcriptomic slides to single-cell level.
• Spatial organisation prediction models highlight the different spatial cellular regions within the tumour (e.g. stromal, tumour core, tumour front).